Cannabis Clinical Trials for Glaucoma
GlauCanna is a R&D venture funded by Mentor Capital, Inc. (OTCQX: MNTR), driven to support the development of treatments for individuals suffering from glaucoma. Through clinical trials, this venture aims to scientifically record the positive outcomes that patients have experienced when their glaucoma condition is treated with cannabis oil, which has been shown to reduce intraocular pressure and the disease’s painful symptoms. This research is derived from clinical trials and by engaging with experts who have been life-long champions of care, such as Dr. Mandelkorn. Combined with Mentor Capital’s funding, this venture aims to create a realistic pathway for change and discoveries in the glaucoma field and in the medical marijuana sector.
One of the first steps in this research will be the development of a dose response curve that can be used to standardize the relationship between cannabis oil dosages and the reduction of intraocular pressure. The hope is that this curve will inform future glaucoma endeavors for years to come.
Dr. Mandelkorn has already observed a 40% reduction in intraocular pressure. His observation shows that the treatment already has the potential to bring the human eye back into the normal range of intraocular pressure to provide considerable relief to the patients who had already saturated their existing medication.
If you would like to be part of GlauCanna's clinical trial please contact Dr. Mandelkorn at his Fort Myers or Punta Gorda Office.
Fort Myers Office
Punta Gorda Office
Dr. Robert Mandelkorn has devoted his entire professional life to eye care. As both an eye surgeon and an eye physician, Dr. Mandelkorn's expertise in the field is well established. Furthering knowledge of the practice, his work has contributed to several books on glaucoma, including Secondary Glaucomas, Contemporary Issues in Ophthalmology, and Clinical Pathways in Glaucoma. Additionally he has been honored with a Lifetime Achievement Award from the American Academy of Ophthalmology. You can find out more on Dr. Mandelkorn at his website here
Mentor Capital, Inc. seeks to come alongside and assist private medical marijuana and cannabis companies and their founders in meeting their liquidity and financial objectives, to add protection for investors and to help incubate private cannabis companies. As a venture of Mentor Capital, GlauCanna will hold an 80% interest in all opportunities springing from this venture. You can find more information about Mentor Capital at its website here.
SAFE HARBOR STATEMENT: Certain statements contained on this web site, including statements regarding administrative steps, events, and financial trends that may affect Mentor Capital, Inc.’s future operating results, financial position, stock price and cash flows, may constitute forward-looking statements within the meaning of the federal securities laws. These statements are based on our assumptions and estimates and are subject to risks and uncertainties. You can identify these forward-looking statements by the use of words like “strategy,” “expects,” “plans,” “believes,” “will,” “would”, “looks”, “estimates,” “intends,” “feels,” “projects,” “goals,” “targets,” “hopes,” “seeks”, and other words of similar meaning. Pro forma projections of an individual or generic investor’s investment performance always are completely uncertain. Similarly, pro forma projections of splits, electronic share deposits, and timing of initiation of warrant trading, for example, in order to explain the sequence and timing of facilitated share trading and warrant exercise, are always completely uncertain. You can also identify these and other forward statements by the fact that they do not relate strictly to historical or current facts. For these statements, we claim the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995.